By Ben Glickman
Shares of ALX Oncology rose Monday after the company said it would discuss interim Phase 2 trial results on a call Tuesday.
The stock was up 18% to $5.68 in after-hours trading, and were up 0.2% at Monday’s close. The shares are down 57% this year.
The South San Francisco, Calif.-based company said late Monday that it would discuss the results from its trial of using evorpacept to treat HER-2-positive gastric cancer.
The company had said that results from the Phase 2 trial were expected in the fourth quarter.
ALX Oncology has previously said that positive results from the trial would support evorpacept’s mechanism of action when combined with certain antibodies, which would boost other development opportunities at the company.
Write to Ben Glickman at [email protected]
Read the full article here
